Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Terminated
115 enrolled 15 charts
AcceleRET-Lung
Phase 3 Terminated
223 enrolled 18 charts
PEMDA-HN
Phase 2 Terminated
69 enrolled 21 charts
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Phase 2 Terminated
14 enrolled
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
PEACH
Phase 1 Terminated
3 enrolled 12 charts
ELEVATE HNSCC
Phase 2 Terminated
193 enrolled 27 charts
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Phase 2 Terminated
4 enrolled 11 charts
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Phase 2 Terminated
59 enrolled 18 charts
BelieveIT-201
Phase 2 Terminated
27 enrolled
Pembrolizumab in HNSCC With Residual Disease After Radiation
Phase 2 Terminated
9 enrolled 15 charts
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
Phase 2 Terminated
6 enrolled
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Terminated
24 enrolled 18 charts
RAPTOR
Phase 1 Terminated
27 enrolled
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Phase 2 Terminated
205 enrolled 54 charts
STARLING
Phase 1 Terminated
31 enrolled
Study of ALE.C04 in Patients With Head and Neck Cancer
Phase 1/2 Terminated
21 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Phase 1/2 Terminated
12 enrolled 8 charts
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
Phase 2 Terminated
16 enrolled
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
119 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
INDUCE-4
Phase 3 Terminated
117 enrolled 33 charts
INDUCE-3
Phase 3 Terminated
315 enrolled 31 charts
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
Phase 2 Terminated
5 enrolled 17 charts
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Terminated
127 enrolled
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
20 enrolled
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Phase 1 Terminated
13 enrolled
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
Phase 1/2 Terminated
2 enrolled
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
5 enrolled
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Phase 1 Terminated
66 enrolled
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Phase 2 Terminated
14 enrolled 12 charts
Safety Study of SEA-CD40 in Cancer Patients
Phase 1 Terminated
159 enrolled
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
Phase 2 Terminated
2 enrolled
Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN
Phase 1/2 Terminated
25 enrolled 14 charts
ELDORANDO
Phase 2 Terminated
47 enrolled
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Phase 2/3 Terminated
1 enrolled 6 charts
ILIAD
Phase 1 Terminated
21 enrolled
A Study of LY3435151 in Participants With Solid Tumors
Phase 1 Terminated
2 enrolled 8 charts
SYNERGY-001
Phase 1/2 Terminated
241 enrolled 23 charts
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Phase 1/2 Terminated
4 enrolled
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled 4 charts
ORKA
Phase 2 Terminated
2 enrolled 5 charts
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Phase 1 Terminated
47 enrolled
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Phase 2 Terminated
1 enrolled